ProShare Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$276K	Sell	89,793 -2,449	-3%	-$9.46K	﹤0.01%	1385
2025 Q4	$377K	Buy	92,242 +14,303	+18%	+$70.8K	﹤0.01%	1307
2025 Q3	$380K	Sell	77,939 -6,614	-8%	-$34.7K	﹤0.01%	1269
2025 Q2	$428K	Buy	84,553 +12,300	+17%	+$60.4K	﹤0.01%	1206
2025 Q1	$382K	Sell	72,253 -15,905	-18%	-$116K	﹤0.01%	1246
2024 Q4	$596K	Buy	88,158 +26,847	+44%	+$181K	﹤0.01%	1173
2024 Q3	$404K	Buy	61,311 +28,434	+86%	+$204K	﹤0.01%	1269
2024 Q2	$247K	Sell	32,877 -8,072	-20%	-$70.4K	﹤0.01%	1415
2024 Q1	$408K	Buy	40,949 +5,051	+14%	+$56.2K	﹤0.01%	1210
2023 Q4	$354K	Buy	35,898 +4,829	+16%	+$34.4K	﹤0.01%	1265
2023 Q3	$238K	Buy	31,069 +1,372	+5%	+$13.7K	﹤0.01%	1358
2023 Q2	$222K	Buy	29,697 +895	+3%	+$6.26K	﹤0.01%	1469
2023 Q1	$192K	Sell	28,802 -3,809	-12%	-$30.2K	﹤0.01%	1468
2022 Q4	$251K	Buy	32,611 +3,707	+13%	+$36.4K	﹤0.01%	1341
2022 Q3	$308K	Buy	28,904 +954	+3%	+$9.66K	﹤0.01%	1136
2022 Q2	$227K	Sell	27,950 -10,157	-27%	-$68K	﹤0.01%	1395
2022 Q1	$272K	Sell	38,107 -9,542	-20%	-$101K	﹤0.01%	1692
2021 Q4	$816K	Buy	+47,649	New	+$897K	﹤0.01%	1155
2021 Q3	–	Sell	-5,482	Closed	-$200K	–	2219
2021 Q2	$200K	Buy	+5,482	New	+$162K	﹤0.01%	2144